Albumin Protects Against Deadly ‘Black Fungus’ – New Discovery Offers Treatment Hope

A common blood protein, albumin, appears to play a surprisingly powerful role in defending the body against mucormycosis, a rare but devastating fungal infection often called “black fungus.” This discovery, published in Nature, could lead to new strategies for preventing and treating a disease that gained notoriety during the COVID-19 pandemic, particularly in India.

Mucormycosis is caused by molds belonging to the Mucorales order. These fungi can invade the sinuses, lungs, and brain, causing tissue damage and, in many cases, death. The infection is particularly dangerous for individuals with weakened immune systems, diabetes, or malnutrition. During the surge of COVID-19 in India in 2021, a particularly high number of mucormycosis cases were reported, overwhelming healthcare systems. The infection remains a serious threat, with a mortality rate reaching as high as 50% in some patient groups.

Albumin Levels as a Critical Indicator

Researchers found a strong correlation between low levels of albumin in the blood – a condition known as hypoalbuminemia – and a significantly increased risk of death from mucormycosis. This finding emerged from an analysis of patients across multiple continents, suggesting the link isn’t limited to a specific geographic region or population. The study, led by George Chamilos, MD, at the University of Crete and the Institute of Molecular Biology and Biotechnology, and with key contributions from Professor Ashraf Ibrahim, PhD, at The Lundquist Institute for Biomedical Innovation, identified hypoalbuminemia as the strongest predictor of severe outcomes.

“This is a remarkable finding and has the potential to change the way clinicians care for mucormycosis,” said Dr. Ibrahim in a statement. The research suggests that monitoring albumin levels could help doctors identify patients at high risk of developing severe disease, allowing for earlier intervention.

How Albumin Fights the Fungus

The study goes beyond simply identifying a correlation; it also begins to explain how albumin protects against mucormycosis. Laboratory experiments demonstrated that albumin actively suppresses the growth of Mucorales fungi without harming other types of microbes. When albumin was removed from human blood samples, the fungus flourished. Conversely, mice lacking albumin were far more susceptible to infection, while restoring albumin levels provided significant protection.

Crucially, the antifungal activity of albumin appears to depend on fatty acids attached to the protein. These fatty acids disrupt fungal metabolism and prevent the production of proteins the fungus needs to invade tissues and cause disease. Researchers observed that patients with mucormycosis had elevated levels of fatty acid oxidation, potentially indicating the fungus was actively working to overcome albumin’s defenses. This suggests a dynamic interplay between the host’s albumin and the invading fungus.

A Previously Unknown Defense Mechanism

The findings reveal a previously unrecognized natural defense mechanism within the human body. Albumin, already known for its role in maintaining blood volume and transporting various substances, now appears to be a key component of the innate immune system’s response to fungal infections. This discovery challenges existing understanding of how the body combats mucormycosis and opens new avenues for therapeutic intervention.

Beyond Albumin: Potential for Combined Therapies

The research team is exploring the possibility of combining albumin treatment with immunotherapies specifically designed to target the virulence factors of Mucorales fungi. Investigators at The Lundquist Institute are currently developing such immunotherapies. The idea is that albumin could suppress fungal growth while the immunotherapy helps the immune system eliminate the remaining infection. This combined approach could be particularly effective in patients with compromised immune systems who are most vulnerable to mucormycosis.

What Does This Imply for Patients?

While these findings are promising, it’s important to emphasize that albumin therapy is not yet a standard treatment for mucormycosis. Further research is needed to determine the optimal dosage, timing, and delivery method for albumin administration. Clinical trials will be necessary to confirm the effectiveness and safety of this approach in humans.

Currently, the standard treatment for mucormycosis involves antifungal medications, often administered intravenously, and surgical removal of infected tissue. Early diagnosis and aggressive treatment are crucial for improving outcomes. Patients with risk factors for mucormycosis – such as diabetes, weakened immune systems, or recent COVID-19 infection – should be vigilant for symptoms, which can include sinus congestion, facial pain, fever, and vision changes. Prompt medical attention is essential.

Public Health Implications and Ongoing Research

The surge in mucormycosis cases during the COVID-19 pandemic highlighted the importance of understanding and addressing this often-overlooked fungal infection. The World Health Organization (WHO) has issued guidance on the prevention and treatment of mucormycosis, emphasizing the need for early diagnosis, appropriate antifungal therapy, and management of underlying risk factors. Ongoing surveillance is crucial for monitoring the incidence of mucormycosis and identifying emerging trends.

Researchers are continuing to investigate the role of albumin in mucormycosis, exploring the specific mechanisms by which it inhibits fungal growth and identifying potential biomarkers that could predict disease severity. The ultimate goal is to develop more effective and targeted therapies for this life-threatening infection. The next steps involve larger clinical trials to validate these findings and determine the best way to translate this discovery into improved patient care.